IgG response to spike protein of SARS-CoV-2 in healthy individuals and potential of intravenous IgG as treatment for COVID-19

BACKGROUND: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19), which is currently a worldwide pandemic. There are limited available treatments for severe COVID-19 patients. However, some evidence suggests that intravenous immunoglobu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Gang, He, Zebao, Wu, Fengtian, Ge, Zhengming, Zhu, Jiansheng, Chen, Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655819/
https://www.ncbi.nlm.nih.gov/pubmed/36372879
http://dx.doi.org/10.1186/s12985-022-01921-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655819/
https://www.ncbi.nlm.nih.gov/pubmed/36372879
http://dx.doi.org/10.1186/s12985-022-01921-z

Ejemplares similares